These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37937429)

  • 1. Perspectives for the creation of a new type of vaccine preparations based on pseudovirus particles using polio vaccine as an example.
    Zhdanov DD; Ivin YY; Shishparenok AN; Kraevskiy SV; Kanashenko SL; Agafonova LE; Shumyantseva VV; Gnedenko OV; Pinyaeva AN; Kovpak AA; Ishmukhametov AA; Archakov AI
    Biomed Khim; 2023 Nov; 69(5):253-280. PubMed ID: 37937429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protease-Independent Production of Poliovirus Virus-like Particles in Pichia pastoris: Implications for Efficient Vaccine Development and Insights into Capsid Assembly.
    Sherry L; Swanson JJ; Grehan K; Xu H; Uchida M; Jones IM; Stonehouse NJ; Rowlands DJ
    Microbiol Spectr; 2023 Feb; 11(1):e0430022. PubMed ID: 36507670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of formaldehyde inactivation on poliovirus.
    Wilton T; Dunn G; Eastwood D; Minor PD; Martin J
    J Virol; 2014 Oct; 88(20):11955-64. PubMed ID: 25100844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of formaldehyde-inactivated poliovirus preparations made from live-attenuated strains.
    Martín J; Crossland G; Wood DJ; Minor PD
    J Gen Virol; 2003 Jul; 84(Pt 7):1781-1788. PubMed ID: 12810872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Newcastle Disease Virus-Based Vectored Vaccine against Poliomyelitis.
    Viktorova EG; Khattar SK; Kouiavskaia D; Laassri M; Zagorodnyaya T; Dragunsky E; Samal S; Chumakov K; Belov GA
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29925653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure and immunogenicity of experimental foot-and-mouth disease and poliomyelitis vaccines.
    Twomey T; Newman J; Burrage T; Piatti P; Lubroth J; Brown F
    Vaccine; 1995 Nov; 13(16):1603-10. PubMed ID: 8578849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decision analysis in planning for a polio outbreak in the United States.
    Jenkins PC; Modlin JF
    Pediatrics; 2006 Aug; 118(2):611-8. PubMed ID: 16882814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inactivation of poliovirus with beta-propiolactone.
    Jiang SD; Pye D; Cox JC
    J Biol Stand; 1986 Apr; 14(2):103-9. PubMed ID: 3020055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis.
    Ciapponi A; Bardach A; Rey Ares L; Glujovsky D; Cafferata ML; Cesaroni S; Bhatti A
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011260. PubMed ID: 31801180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural and Immunoreactivity Properties of the SARS-CoV-2 Spike Protein upon the Development of an Inactivated Vaccine.
    Kordyukova LV; Moiseenko AV; Serebryakova MV; Shuklina MA; Sergeeva MV; Lioznov DA; Shanko AV
    Viruses; 2023 Feb; 15(2):. PubMed ID: 36851694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intradermal fractional-dose inactivated polio vaccine (fIPV) adjuvanted with double mutant Enterotoxigenic Escherichia coli heat labile toxin (dmLT) is well-tolerated and augments a systemic immune response to all three poliovirus serotypes in a randomized placebo-controlled trial.
    Crothers JW; Ross Colgate E; Cowan KJ; Dickson DM; Walsh M; Carmolli M; Wright PF; Norton EB; Kirkpatrick BD
    Vaccine; 2022 Apr; 40(19):2705-2713. PubMed ID: 35367069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beta-Propiolactone Inactivation of Coxsackievirus A16 Induces Structural Alteration and Surface Modification of Viral Capsids.
    Fan C; Ye X; Ku Z; Kong L; Liu Q; Xu C; Cong Y; Huang Z
    J Virol; 2017 Apr; 91(8):. PubMed ID: 28148783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Equivalent schedules of intradermal fractional dose versus intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis.
    Jaiswal N; Singh S; Agarwal A; Chauhan A; Thumburu KK; Kaur H; Singh M
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011780. PubMed ID: 31858595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of three aluminium hydroxide adjuvanted vaccines with reduced doses of inactivated polio vaccine (IPV-Al) compared with standard IPV in young infants in the Dominican Republic: a phase 2, non-inferiority, observer-blinded, randomised, and controlled dose investigation trial.
    Rivera L; Pedersen RS; Peña L; Olsen KJ; Andreasen LV; Kromann I; Nielsen PI; Sørensen C; Dietrich J; Bandyopadhyay AS; Thierry-Carstensen B
    Lancet Infect Dis; 2017 Jul; 17(7):745-753. PubMed ID: 28454674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electrochemical profiling of poliovirus particles inactivated by chemical method and ionizing radiation.
    Agafonova LE; Shumyantseva VV; Ivin YY; Piniaeva AN; Kovpak AA; Ishmukhametov AA; Budnik SV; Churyukin RS; Zhdanov DD; Archakov AI
    Biomed Khim; 2024 Jun; 70(3):161-167. PubMed ID: 38940205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increasing Type 1 Poliovirus Capsid Stability by Thermal Selection.
    Adeyemi OO; Nicol C; Stonehouse NJ; Rowlands DJ
    J Virol; 2017 Feb; 91(4):. PubMed ID: 27928008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New generation of inactivated poliovirus vaccines for universal immunization after eradication of poliomyelitis.
    Chumakov K; Ehrenfeld E
    Clin Infect Dis; 2008 Dec; 47(12):1587-92. PubMed ID: 18990066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physicochemical Characterization of Sabin Inactivated Poliovirus Vaccine for Process Development.
    Torisu T; Shikama S; Nakamura K; Enomoto K; Maruno T; Mori A; Uchiyama S; Satou T
    J Pharm Sci; 2021 May; 110(5):2121-2129. PubMed ID: 33340531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Future of polio vaccines.
    Ehrenfeld E; Modlin J; Chumakov K
    Expert Rev Vaccines; 2009 Jul; 8(7):899-905. PubMed ID: 19545205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new WHO International Reference Reagent for use in potency assays of inactivated poliomyelitis vaccine.
    Wood DJ; Heath AB; Kersten GF; Hazendonk T; Lantinga M; Beuvery EC
    Biologicals; 1997 Mar; 25(1):59-64. PubMed ID: 9167009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.